RxDoctor Payments Data

Mohanad Eltahir, DPM

Foot & Ankle Surgery · Tucson, AZNPI 1649634320

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $15,684 of the $23,589 with a category attached, or 66.5%. 30 manufacturers reported payments, led by Stryker at 29.2% of the total. 2025 is the largest year on record at $8,648, 2.0 times the $4,321 reported in 2019.

$23,589in general payments, 2019–2025

Across 246 payments — averaging $95.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$7K
  • Smith+Nephew$4K
  • Treace Medical Concepts, Inc.$3K
  • Vilex LLC$3K
  • Paragon 28, Inc.$3K
  • Arteriocyte Medical Systems, Inc.$1K
  • plus $3K from 24 others

What the payments were for

  • Travel & lodging$15,68466%
  • Food & beverage$7,90534%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,589 in reported general payments places this provider in the 85th percentile of 291 foot & ankle surgery providers in Arizona.

See all foot & ankle surgery providers in Arizona

Medicare billing

Part B allowed, 2024
$43,928
Medicare patients
63
Services billed
429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.13$23,287
Ciclopirox24$981
CiclopiroxCiclopirox Olamine23$371
Ammonium Lactate20$364
Doxycycline Hyclate19$182
Mupirocin19$152
Cephalexin14$135
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim11$106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$3,911$23,28713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 291 foot & ankle surgery providers in Arizona.

Other foot & ankle surgery in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →